Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

NCT05104983 is registered in ClinicalTrials.gov with Darcy Krueger as lead sponsor.

NCT NCT05104983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05104983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Lead sponsor
Darcy Krueger
Phase
Phase 2
Overall status
Recruiting
Start date
October 13, 2021
Completion date
June 30, 2028
Enrollment
64 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, tuberous sclerosis complex